title: Retrospective analysis of concurrent chemoradiation with the combination of bleomycin, ifosfamide and cisplatin (BIP) for uterine cervical cancer.
abstract: Combination chemotherapy consisting of bleomycin, ifosfamide, and ciplatin (BIP) is recognized as one of the most effective chemotherapies for uterine cervical cancer. However, there have been no reports that evaluate concurrent use of radiation with BIP. The objective of this study was to evaluate the toxicity and response of the combination of BIP concurrent with radiation in patients with squamous cell carcinoma of the uterine cervix. Eligibility criteria included patients who underwent radical hysterectomy (Type III hysterectomy) as a primary treatment and revealed lymph node metastases or deep myometrial invasion (stage IB and IIA) and patients who were previously untreated (stage IIB-IV). All of the patients had biopsy-proven squamous cell carcinoma of the uterine cervix. The patients received three courses of BIP chemoradiation, and the response and toxicity were evaluated. From January 2000 to December 2003, 30 patients met study eligibility criteria. All but three patients completed 3 courses of planned chemotherapy. The frequency of severe (grade 3 and 4) toxicity was as follows: anemia, 46.7%; neutrocytopenia, 73.3%; thrombocytopenia, 16.7%; and nausea and vomiting, 23.3%. Among 30 patients, 22 cases were evaluated for response. Complete response was achieved in 16 (72.7%) of patients, with a response rate of 90.9%. In conclusion, BIP chemoradiation seems to be superior to previously reported chemoradiation regimens, and has a potential as an optimal combination chemotherapy concurrent with radiation.
authors.affiliation: Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
authors.forename: Michiko
authors.initials: M
authors.lastname: Aoki
authors.forename: Jun-Ichi
authors.initials: J
authors.lastname: Akahira
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Niikura
authors.forename: Sumika
authors.initials: S
authors.lastname: Saito
authors.forename: Yoriko
authors.initials: Y
authors.lastname: Abe
authors.forename: Takeshi
authors.initials: T
authors.lastname: Aida
authors.forename: Naoko
authors.initials: N
authors.lastname: Sato
authors.forename: Takako
authors.initials: T
authors.lastname: Kitamura
authors.forename: Kenro
authors.initials: K
authors.lastname: Otsuki
authors.forename: Atsuko
authors.initials: A
authors.lastname: Katahira
authors.forename: Hiroki
authors.initials: H
authors.lastname: Utsunomiya
authors.forename: Chikako
authors.initials: C
authors.lastname: Okamura
authors.forename: Tadao
authors.initials: T
authors.lastname: Takano
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Ito
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Okamura
authors.forename: Nobuo
authors.initials: N
authors.lastname: Yaegashi
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D001761:Bleomycin; D002945:Cisplatin; D007069:Ifosfamide